

## Friday October 2<sup>nd</sup>

08.30 Welcome coffee

08.45 Introduction, *Philippe Métellus*

---

### 09.00 Basic and translational research session

---

*Chairs: Manuel Valiente & Kim Margolin*

09.00 Preclinical Insights into Brain Metastases of Breast Cancer,  
*Brunilde Gril*

09.30 Genomics of Brain Metastases, *Priscilla Brastianos*

10.00 A new pharmacological approach in Brain Metastases,  
*Frits Thorsen & Rolf Bjerkvig*

10.30 Coffee break and visit of the exhibition

*Chairs: Francesco Di Meo & Priscilla Brastianos*

11.00 **Keynote lecture:** Molecular regulation of the critical steps  
to initiate Brain Metastases, *Manuel Valiente*

11.30 Brain Metastases phenotypic heterogeneity,  
*Jacek Jassem & Renata Duchnowska*

12.00 Lunch

12.30 Symposium

*Chairs: Jan Eskandari & Philippe Métellus*



CyberKnife radiosurgery for single and multiple cerebral metastases - experiences of the Maria Sklodowska-Curie Memorial Cancer Center, *Slawomir Blamek*  
Experience in Brain Metastases treatment with the CyberKnife, *Alfredo Conti*

---

### 13.30 Parallel academic workshop: expert driven sessions

---

- 13.30 **Team A:** Trial design, end points and inclusion criteria,  
*Riccardo Soffietti & Manmeet Ahluwalia*
- Team B:** Combined systemic and local therapies,  
*Matthias Preusser & Caroline Chung*
- Team C:** Preventive trials design, *Frank Winkler & Minesh Mehta*
- 

### 14.30 Academic workshop feedback and discussion

---

- 14.30 **Team A:** Trial design, end points and inclusion criteria,  
*Riccardo Soffietti & Manmeet Ahluwalia*
- Team B:** Combined systemic and local therapies,  
*Matthias Preusser & Caroline Chung*
- Team C:** Preventive trials design, *Frank Winkler & Minesh Mehta*
- 

### 16.00 Therapeutic session

---

*Chairs: Philippe Métellus, Matthias Preusser & Manfred Westphal*

- 16.00 Targeted therapies in Brain Metastases, *Manmeet Ahluwalia*
- 16.30 The value of 5-ALA induced fluorescence for resection  
of Brain Metastases, *Georg Widhalm*
- 17.00 Preventive strategies for neurocognitive deficits  
in the management of Brain Metastases, *Minesh Mehta*
- 17.30 **Keynote lecture:** Emerging role of immunotherapies in Brain  
Metastatic Melanoma, *Kim Margolin*
- 

### 18.00 Poster session

---

Guided poster walks, cheese & wine

20.00 Gala dinner

## Saturday October 3<sup>rd</sup>

08.00 Welcome coffee

08.30 TTFIELDS for treatment of primary and metastatic brain tumors – an Update, *Zvi Ram*

---

### 08.45 Selected oral presentations

---

*Chairs: Frédéric Dhermain & Zvi Ram*

08.45 Pro-metastatic role of LFA-1 in Brain Metastases progression unmasks the potential use of anti-nos and anti-cox therapies, *Manuel Sarmiento Soto, United Kingdom*

08.55 Identification and characterization of Brain Metastases initiating cells, *Anna Sophie Berghoff, Germany*

09.05 Flow cytometry assays in CSF improve diagnostic accuracy of leptomeningeal metastases from epithelial tumors and melanoma, *Dieta Brandsma, The Netherlands*

09.15 Human epidermal growth factor receptor type 2 and hormonal receptors discordances between primary breast cancer and its Brain Metastases, *Christophe Joubert, France*

09.25 Effect of GAP27 on breast cancer Brain Metastases development: initial results, *Valérie De Meulenaere, Belgium*

09.35 Development and application of a novel model of human lung-to-Brain Metastases to identify unique metastatic gene signatures, *Mohini Singh, Canada*

09.45 Molecular detection enables intravital diagnosis in a novel pre-clinical mouse model of spontaneous melanoma Brain Metastases, *Hila Schwartz, Israel*

09.55 Laboratory parameters have prognostic value in patients with newly diagnosed Brain Metastases: analysis of 1201 cases, *Romina Koller, Austria*

10.05 T cell response facilitates cerebral metastasis of breast cancer, *Dana Mustafa, The Netherlands*

10.15 Coffee break and visit of the exhibition

*Chairs: Émilie Le Rhun & Philippe Métellus*

- 10.45 RTOG 1119: phase II randomized study of whole brain radiation therapy with concurrent lapatinib in patients with Brain Metastases from HER2+ breast cancer – A collaborative study of NRG and KROG (NCT01622868), *Kim In Ah, South Korea*
- 10.55 Stereotactic fractionated radiotherapy of the resection cavity in patients with one to three Brain Metastases, *Angelika Bilger, Germany*
- 11.05 Tumor subtype and others prognostic factor for the development of Brain Metastases from breast cancer patients in Indonesia, *Rini Andriani, Indonesia*
- 11.15 Surgical resection of Brain Metastases from renal cancer: is it worth it? A French Cancer Center experience, *Lauriane Eberst, France*
- 11.25 NRG CC001: phase III trial memantine and whole-brain radiotherapy with or without hippocampal avoidance in patients with Brain Metastases, *Minesh P. Mehta, USA*
- 11.35 The dynamics of resolution of metastases-associated edema after surgery vs. SRS, *Rachel Grossman, Israel*
- 11.45 Immune response in breast cancer Brain Metastases and their microenvironment, *Renata Duchnowska, Poland*
- 11.55 AZD3759, an egfr inhibitor with blood brain barrier (BBB) penetration, for the treatment of EGFR+ non-small cell lung cancer (NSCLC) with Brain Metastases (BM) and leptomeningeal metastases (LM) – Ongoing phase I study, *Sarit Rabbie, United Kingdom*
- 12.05 Fluorescein sodium-guided resection of cerebral metastases – Experience with first 51 patients, *Julius Hoehne, Germany*
- 12.15 Treatment of *EGFR/ALK*-driven non-small cell lung cancer (NSCLC) Brain Metastases: impact of first-line whole brain radiotherapy on outcome, *Mark K. Doherty, Canada*
- 12.25 **Keynote lecture:** Perspectives in Breast Cancer Brain Metastases research approaches, *David Cameron*

---

**12.55 Awards – Best communication and poster – Conclusions**


---

*Chair: Philippe Métellus*